Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation

a technology of atrial fibrillation and mexiletine, which is applied in the direction of amide active ingredients, drug compositions, cardiovascular disorders, etc., can solve the problems of insufficient elimination of atrial fibrillation and higher reoccurrence rate of atrial fibrillation, so as to reduce the risk of ventricular arrhythmias, improve treatment, and suppress tdp

Active Publication Date: 2017-03-30
FB HRS LLC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a new discovery that the combination of two drugs, mexiletine and dofetilide, works better in treating atrial fibrillation, a condition that can cause heart rhythm problems. This combination can be more effective and safer than using dofetilide alone, reducing the risk of serious side effects. The new treatment involves giving the drugs together or separately, as long as they are given at the same time. This combination can improve the effectiveness of treating atrial fibrillation with fewer side effects.

Problems solved by technology

Both approaches have advantages and disadvantages, and both are insufficient to eliminate atrial fibrillation.
There is a higher reoccurrence rate of atrial fibrillation when patients are treated with drug therapy than radiofrequency ablation due to relatively poor efficacy and incidence of adverse effects of drugs for the management of atrial fibrillation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
  • Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
  • Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation

Examples

Experimental program
Comparison scheme
Effect test

example

Arterially Perfused Rabbit Atrial Wedge Preparations and Electrophysiologic Recordings

[0074]Animal research data demonstrate that use of dofetilide with mexiletine, a drug that blocks cardiac sodium current, can significantly increase the effective refractory period (ERP) in rabbit atrial tissue. ERP is a most important parameter in cardiac electrophysiology that determines vulnerability of cardiac tissues for the development of arrhythmias including atrial fibrillation. A longer ERP results in better treatment and prevention of cardiac arrhythmias. The synergistic effect of dofetilide and mexiletine on atrial ERP can more effectively suppress atrial fibrillation than dofetilide alone. Additionally, mexiletine, due to its inhibitory effect on late sodium current, can significantly reduce the risk of TdP associated with dofetilide treatment based on recent studies,11 the entire content of which is incorporated herein by reference.

Materials and Method

[0075]Rabbits (New Zealand White) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
action potentialaaaaaaaaaa
SEMaaaaaaaaaa
Login to View More

Abstract

Effective and safe pharmaceutical composition and method for treating atrial fibrillation are described. The combined use of dofetilide and mexiletine resulted in an enhanced efficacy in the prevention and treatment of atrial fibrillation with markedly reduced risk of the life-threatening ventricular arrhythmia TdP.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is entitled to priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 222,973, filed Sep. 24, 2015, the disclosure of which is hereby incorporated by reference herein in its entirety.BACKGROUND OF THE INVENTION[0002]Atrial fibrillation is the most common abnormal heart rhythm affecting approximately 5.2 million people in United States, more than 10 million in China1,2 and 33 million world-wide.3 Despite improvements in primary and secondary prevention of coronary artery disease, and effective treatment of hypertension and other heart diseases, the prevalence of atrial fibrillation continues to rise. The rise in atrial fibrillation may, at least in part, be due to the longer average life span of humans. It is projected that atrial fibrillation prevalence will increase to 12.1 million cases in 2030 in the US.4 Atrial fibrillation predisposes patients, particularly elders, to a higher risk for s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/18A61K9/00A61K9/48A61K31/138
CPCA61K31/18A61K9/48A61K9/0053A61K31/138A61P43/00A61P9/00A61P9/06A61K2300/00
Inventor YAN, GANXINDONG, JIAN-ZENGMA, CHANG-SHENG
Owner FB HRS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com